Galileo Resources soars higher as initial drilling at Concordia copper project completed
A look at some of the biggest London-listed risers and fallers today
Company
Pfizer Inc
NYSE:PFE
Pfizer Inc is a research-based biopharmaceutical company. The company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1.
293 stories · page 12 of 15
FTSE 100 dragged lower as Brexit worries whirl; Sainsbury's weighs
The FTSE 100 closed 15.52 down at 7,234 with Sainsbury's and mining shares under pressure
US shares end higher as Fed in focus; US crude tanks
Wall Street shares finished higher as markets look to the Fed meeting and another host of earnings
US shares end up as oil investors crowd out depressed pharma post-Trump speech
US shares ended higher on Wednesday, as energy investors shrugged off a jump in US oil stocks, and markets took a sanguine view of President-elect Donald Trump’s first speech since he won the November election
Allergan to buy LifeCell for $2.9bn cash
Allergan, the maker of wrinkle-filler Botox, said on Tuesday that it has agreed to buy regenerative medicine company LifeCell for $2.9bn in cash
GlaxoSmithKline’s fast-growing HIV drug business gets another boost
Glaxo has developed the new two-drug cocktail through its majority-owned ViiV Healthcare joint venture, in which US firm Pfizer and Japan’s Shionogi also hold stakes.
Archive
Trending: Trump pledges to fight the drug companies
After his Nov. 9 victory investors jumped out of tech stocks and flocked to banks expected to benefit from deregulation, gun-makers on the hope that he won’t curb their sales, and pharmaceutical stocks on the understanding that Trump was ne
Archive
Trending - fines, HSBC, JP Morgan, Pfizer and bird flu
A look at some of the big, trending topics on Wednesday
Trending: Which 80 small- mid- and large-cap stocks will do well over four years?
Watching the way Wall Street index tickers have raced to fresh record highs on both Monday and Tuesday, investors might be forgiven for thinking that pretty much any stock is doing well on the so-called “Trump Trade”, coined in the wake of
US stocks end mixed as winners and losers assess Trump
US stocks seesawed through Thursday, with the Dow hitting a record high intraday and close, as banks and pharma stocks lapped up the perceived benefits of President-elect Donald Trump’s victory, while tech stocks sank on worries about his f
US small-caps among the top risers after Trump victory
US stocks snapped back from initial losses to close Wednesday higher and the Dow even managed an intraday record peak, while small-caps had one of their best days in 14 years, after Donald Trump and the Republicans’ sweep into office
Pfizer trims 2016 profit forecast as it scraps cholesterol drug
The US drug maker has knocked five cents off of its per share earnings forecast for this year
Pfizer’s spoiler on Johnson & Johnson’s earnings rally
The world’s largest healthcare company Johnson & Johnson’s third-quarter earnings per share came in 3 cents higher than analysts’ forecasts. But Pfizer said it will launch a cheaper competing product to J&J's flagship drug Remicade
US stocks gain in healthy sector rally
US stocks ended higher on Tuesday with a boost from high drama in the healthcare sector
Pharmas Regeneron and Teva shares hit by FDA order
Shares of Regeneron Pharmaceuticals and Teva Pharmaceuticals were hit Monday by news of a clinical trial setback for a new pain drug they are co-developing
Archive
Pfizer, Etsy and eBay on brokers’ radars
Pfizer bruised by a downgrade from Jefferies but Wedbush assume coverage of eCommerce names eBay and Etsy
AstraZeneca up after diabetes combo passes phase III
The trial met the met the primary endpoint of a better performance that the single medicines alone said the pharma
Merck/Pfizer ready new diabetes drug after trial success
Ertugliflozin is an investigational oral treatment for type 2 diabetes
AstraZeneca to sell antibiotics business to Pfizer
The deal is for its late-stage small molecule antibiotics business and involves three already-approved antibiotics - Merrem, Zinforo and Zavicefta - and two drugs in clinical trials (ATM-AVI and CXL).
Pfizer wins battle for Medivation with US$14bn offer
Medivation has been on the block since April when French group Sanofi offered US$52.50 per share.